Author (Year)

Design /Study Size

Treatment being studied

Mean (Year)

Findings (refer to Figures 2-5)

Anticoagulant therapy and incidence of stroke

Patel, M. R. et al. (2011)

Randomized Clinical trial (n = 14,264)

Rivaroxaban (Xarelto) 20 mg or 15 mg daily for patients with a creatinine clearance of 30 to 49 mL per minute vs. dose adjusted (target international normalized ratio [INR], 2.0 to 3.0) Warfarin

71.2 ± 9.42

(73 years (1/4 of patients were 78 years and older) and 39.7% of the patients were women)

Rivaroxaban was noninferior to Warfarin.

Stroke or systemic embolism occurred in 269 patients in the rivaroxaban group and in 306 patients in the warfarin group (hazard ratio, 0.88; 95% CI, 0.74 to 1.03; P < 0.001 for noninferiority; P = 0.12 for superiority) [12] .

Rutherford, O. C. W. et al. (2020)

Randomized cohort trial

(n = 20,504)

Dabigatranvsrivaroxaban

Dabigatran

70.9 ± 10.95

Rivaroxaban

70.9 ± 11.21

Stroke/SE occurred with an event rate of 1.84/100 person-years compared with 2.21/100 person-years in the rivaroxaban group [HR 0.88; 95% confidence interval (CI) 0.76 - 1.02].